RENAL) TIX \mathbf{A}

Director/PDMR Shareholding

June 22, 2021

RNS Number : 7062C Renalytix AI PLC 22 June 2021

Renalytix Al plc

("Renalytix" or the "Company")

Director/PDMR Dealing

The Company was informed that today, Christopher Mills, a non-executive director and interim Chairman, completed the sale of 17,000 ordinary shares of 0.25 pence each ("Ordinary Shares") in the Company at a price of 113.5 pence per share.

Following completion of the sale, Christopher Mills is interested in 9,180,501 Ordinary Shares representing 12.74% of the current issued share capital of the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person disch closely associated	arging managerial responsibilities / person
a)	Name	Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited as investment manager to North Atlantic Smaller Companies Investment Trust plc and Oryx
2	Reason for the notification	
a)	Position/status	Christopher Mills, non-exec director and Interim Chair of the issuer and director of NASCIT and Oryx International Growth Fund Ltd
b)	Initial notification /Amendment	Initial Notification

3	Details of the issuer, emiss platform, auctioneer or auc	sion allowance market participant, auction ction monitor
a)	Name	Renalytix AI plc
b)	LEI	213800NTOH3FK3WER551
4		s): section to be repeated for (i) each type of of transaction; (iii) each date; and (iv) each place een conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.0025 each
	Identification code	GB00BYWL4Y04
b)	Nature of the transaction	Sale of shares
C)	Currency	GBP
d)	Price(s) and volume(s)	Price(s) Volume(s) 11.352941 17,000
e)	Aggregated information	
	- Aggregated volume	17,000
	- Price	£192,999.99
f)	Date of the transaction	18 June 2021
g)	Place of the transaction	London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <u>rns@lseg.com</u> or visit <u>www.rns.com</u>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

DSHDKBBPCBKKPAB